Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | BLVRB | P30043 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PHLPP2 | Q6ZVD8 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701516 | 0.93 | TRPA1 (0.58) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL31701751 | 0.88 | PHLPP2 (0.50) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL20741612 | 0.87 | TDP1 (0.58) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL12589872 | 0.86 | RXRB (0.45) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL3399265 | 0.85 | CYP3A4 (0.53) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL27671132 | 0.82 | PHLPP2 (0.67) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL30221905 | 0.80 | MEN1 (0.69) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL1602880 | 0.80 | MEN1 (0.69) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL830090 | 0.80 | MEN1 (0.69) | KMT2AMEN1PDE4ABLVRBKDR | |
| SCHEMBL22846462 | 0.80 | RXRB (0.41) | KMT2AMEN1PDE4ABLVRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320236-A1 | METAL ORGANIC FRAMEWORKS (MOFs) AND METHODS OF USE | CONWAY DAVID JONATHAN (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320236-A1 | METAL ORGANIC FRAMEWORKS (MOFs) AND METHODS OF USE | OGFOD1, OCIAD1, MLYCD | KMT2A 1299/4885MEN1 3348/4885PDE4A 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.